The Brazil Drug Discovery Technologies Market was valued at $310.4 Million in 2025 and projected to reach to $449.2 Million by 2030, representing a compound annual growth rate of CAGR 7.7%. Brazil's drug discovery technologies market is poised for steady expansion through 2030, driven by increasing government support for pharmaceutical research and a growing biotechnology ecosystem.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Brazil's drug discovery technologies market is valued at USD 310.4 million in 2025, with projections reaching USD 449.2 million by 2030, representing a robust 7.7% CAGR over the forecast period.
Brazil is establishing itself as a regional hub for drug discovery in Latin America, leveraging its growing biotechnology ecosystem and strategic investments in pharmaceutical research infrastructure.
Government initiatives and increased funding for pharmaceutical research are driving innovation in Brazil's drug discovery sector, creating favorable conditions for technology adoption and R&D expansion.
Brazil's expanding biotechnology sector is accelerating the adoption of advanced drug discovery technologies, positioning the country as a key player in Latin American pharmaceutical innovation.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES (Technology) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 11% from 2025 to 2030 |
| Largest Segment | REAGENTS & CONSUMABLES (Product) |
| Market Size Base Year (Billions) | ~USD 30.57 (2025) |
| Revenue Forecast (Billions) | ~USD 51.51 (2030) |
| Segments Covered | Product, Technology, Type, Process |
4 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 53.8 | 54 | 56.4 | 59.9 | 63.9 | 69 | 75.3 | 83.2 | 8.1 |
| CONTRACT RESEARCH ORGANIZATIONS (CROS) | 123 | 124.6 | 131.3 | 140.9 | 151.8 | 165.4 | 182.3 | 203.6 | 9.2 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 326.2 | 332.2 | 351.6 | 379.1 | 410.3 | 449 | 497.3 | 558.1 | 9.7 |
| TOTAL | 503 | 510.8 | 539.3 | 579.9 | 626.1 | 683.4 | 754.8 | 845 | 9.4 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| MERCK KGAA | Germany | Public Company | Life Science (tools, reagents, bioprocessing, CDMO),Healthcare (oncology, neurology, fertility, rare diseases),Electronics (semiconductor and display materials, gases, equipment), |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| REVVITY | United States | Public Company | Diagnostics instruments and systems,Diagnostics reagents, assays, and kits,Life science reagents and consumables, |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Array-based instruments and consumables, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and related solutions),Life Sciences (instruments, reagents, genomics, and imaging),Diagnostics (clinical instruments, consumables, software, services), |
| BRUKER | United States | Public Company | BSI BioSpin (NMR/EPR and preclinical imaging),BSI CALID (mass spectrometry and diagnostics),BSI Nano (X-ray, AFM, EM analytics, optical microscopy), |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Immune response and infectious disease diagnostics (incl. TB IGRA),Oncology and sexual & reproductive health assays, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Instruments and Systems,Life Science Reagents and Consumables, |
| TAKARA BIO INC. | Japan | Private Company | Research reagents for genetic and cellular research,Instruments (PCR systems, cellular analysis devices),In vitro diagnostics (including COVID-19 testing), |
| CORNING INCORPORATED | United States | Public Company | Optical communications (fiber, cable, connectivity hardware),Display glass substrates (LCD and OLED),Specialty materials and optics, |
| HAMILTON COMPANY | United States | Public Investment Firm | Primary and secondary fund-of-funds,Direct credit and direct investments,Evergreen and customized solutions, |
| PACBIO | United States | Public Company | Long-read instruments (Revio, Sequel, Vega),Long-read consumables and SMRT cells,Short-read Onso platform and consumables, |
Thermo Fisher Scientific Inc. is a leading United States-based life sciences company founded in 1956, employing 125,000 people globally. Operating as a public company, it provides a comprehensive portfolio of products and services for research, diagnostics, and bioproduction.
Merck KGaA is a German multinational science and technology company with roots dating back to 1668, currently employing 59,077 people. As a public company, it operates across pharmaceuticals, life sciences, and performance materials sectors.
Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company specializes in life sciences, diagnostics, and applied chemical markets with analytical instruments and services.
Revvity is a United States public company established in 1937, employing 11,000 people. It provides analytical and diagnostic solutions for life sciences, diagnostics, and applied markets.
Illumina, Inc. is a United States-based public company founded in 1998 with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies for research, diagnostics, and clinical applications.
Danaher Corporation is a diversified United States public company founded in 1969, employing 59,000 people worldwide. It operates across multiple segments including life sciences, diagnostics, environmental and applied solutions.
Bruker is a United States-based public company founded in 1960 with 11,085 employees. It manufactures scientific instruments for molecular and materials research, including mass spectrometry and NMR systems.
QIAGEN is a Netherlands-based public company founded in 1984 with 5,500 employees. It specializes in sample and assay technologies for molecular diagnostics, applied testing, and life sciences research.
Bio-Rad Laboratories, Inc. is a United States public company established in 1952 with 7,450 employees. It develops and manufactures clinical diagnostics and life science research products.
Takara Bio Inc. is a Japanese private company founded in 2002 with 1,779 employees. It develops and manufactures reagents and instruments for life science research and biotechnology applications.
Corning Incorporated is a United States public company with a history dating to 1851, employing 67,200 people. It operates across multiple industries including life sciences, with products for research, diagnostics, and bioproduction.
Hamilton Company is a United States-based public investment firm founded in 1991 with 785 employees. It provides laboratory automation and liquid handling solutions for life sciences and diagnostics.
PacBio is a United States public company founded in 2000 with 485 employees. It develops long-read DNA sequencing systems and services for genomics research and clinical applications.
Brazil's drug discovery technologies market is valued at USD 310.4 million in 2025 and is projected to reach USD 449.2 million by 2030.
Brazil's drug discovery technologies market is expected to grow at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2030.
Brazil's market growth is driven by increased government investment in life sciences, expanding academic-industry collaborations, growing clinical trial capabilities, and adoption of advanced technologies such as AI and high-throughput screening.
Brazil represents the largest and most developed drug discovery technologies market in Latin America, with the most advanced infrastructure, largest patient population, and strongest regulatory framework for pharmaceutical research.
Key technologies in Brazil's market include artificial intelligence, machine learning, high-throughput screening, computational chemistry, and laboratory automation platforms that accelerate the drug discovery process.
The research study involved the wide use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global drug discovery technologies market. Widespread interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size is estimated through secondary research (top-down and bottom-up) followed by data triangulation with inputs from industry experts to arrive at the final market size.
Secondary research was used mainly to identify and collect information for the technical, market-oriented, and commercial study of the drug discovery technologies market. The secondary sources used for this study include World Health Organization (WHO), Association of International Contract Research Organizations (AICROS), American Association of Pharmaceutical Scientists (AAPS), Eurostat, Clinical and Contract Research Association (CCRA), Association of Clinical Research Organizations (ACRO), Pharmaceutical Research and Manufacturers of America (PhRMA), India Brand Equity Foundation (IBEF), National Center for Biotechnology Information (NCBI), Food and Drug Administration (FDA). Academic Journals and Company Websites, corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations among others. These secondary sources were also used to obtain major information about key market players, and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analysed to arrive at the market size of the global drug discovery technologies market, which was further validated through primary research.
Extensive primary research was conducted after acquiring basic knowledge about the global drug discovery technologies market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical & biopharmaceutical industries, academic institutes, and others from the supply side, such as C-level and D-level executives, product/ managers, marketing & sales managers of key manufacturers, distributors, and channel partners. The primary interviews were conducted across six major regions, including North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 60% and 40% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the drug discovery technologies market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Drug discovery is the process of developing a therapeutically active substance for a defined target molecule. Drug discovery is the early phase in which target identification, target validation, hit-to-lead identification, lead optimization, and candidate validation take place to deliver any suitable molecule or candidate for drug development. Drug discovery technologies are provided by contract research organizations (CROs) to pharmaceutical companies.
Full forecast, segment splits, and company analysis for all Drug Discovery Technologies Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report